



Therapeutic Use Exemption (TUE) Documentation For New ADHD Medication(s)

The prescribing physician should be clinically trained and practicing in psychiatry.

For a TUE to be considered for the use of an ADHD medication the following medical information must be submitted to the Independent Program Administrator (IPA) in a legible format for review.

Required are:

- a. Detailed documentation of the clinical symptoms that meet the DSM-5 criteria for the diagnosis; current and past, age of onset of the symptoms, and the clinical significance of the impairment both playing baseball and outside of baseball. An ACDS v1.2 evaluation should be completed. Report any comorbid psychiatric diagnoses or any family history of ADHD.
- b. Evaluation should also include a Barkley Functional Impairment Scale (BFIS) and interview of the player and an additional informant.
- c. Formalized neuropsychological testing is not required at the outset, but may be requested if further elucidation of the player's status is deemed necessary.
- d. Independent verification of the player's symptoms and severity must be obtained either by an interview of a family member of the player or by a second independent clinician's assessment (childhood examiner, current testing psychologist, or second expert clinician).
- e. Results of any laboratory/psychological tests that were obtained in the course of the evaluation. Provide comments on test result abnormalities.
- f. Identify all prior unsuccessful medications taken by the player for ADHD. TUE requested medications should be FDA-approved for adult ADHD. An FDA-approved non-stimulant medication should have been previously considered. Exceptions to the above must have supporting documentation.
- g. A detailed treatment plan that includes the medication for which a TUE is being requested, the dose, the route of administration, and the frequency of the use of the medication. Include when follow-up with the player will occur.
- h. If the player has been on the medication prior to the TUE request, provide an evaluation of the efficacy of the medication used (including dosing and dosing regimen). In addition, any observations and consequences when the medication is not taken for a brief period of time should be reported.

All TUE documentation may be submitted to the IPA at the following address:

Tom Martin, Ph.D.
Independent Program Administrator
Major League Baseball's Joint Drug Prevention and Treatment Program
1016 Omega Farms Lane
Williamston, SC 29697
Email: tom.martin@jdaipa.com
Fax: (757) 903-0164
Questions? Call (808) 203-3302